Last updated: February 20, 2026
What is the Patent Scope and Claims for HRP20080018?
The Croatian patent HRP20080018 covers a medicinal compound or formulation for treating specific oncological conditions. The patent includes claims targeting both the chemical composition and its therapeutic application, emphasizing its novelty in certain combination therapies.
Patent Scope
- Chemical Composition: Encompasses a class of heterocyclic compounds with a defined core structure, substituents, and specific stereochemistry.
- Therapeutic Use: Claims specify use in treating particular cancers, such as breast, lung, or colon carcinomas.
- Method of Production: Covers processes for synthesizing the compounds, emphasizing unique steps that improve yield or purity.
- Formulations: Includes pharmaceutical formulations such as tablets, capsules, or injectable solutions containing the active compound.
Key Claim Elements
| Claim Type |
Description |
| Independent Claims |
Cover the chemical structure, its derivatives, and specific uses. |
| Dependent Claims |
Narrow the scope to specific variants, methods, or formulations. |
| Priority Claim |
Based on earlier applications filed in the UK and Croatia in 2008. |
| Scope of Claims |
Extends to both the compound's chemical properties and its therapeutic application in oncology treatment. |
How does the patent compare to existing patents?
- Broad claims on the chemical class differentiate HRP20080018 from related patents that focus on narrower chemical entities.
- The therapeutic claims encompass multiple indications, expanding potential market applicability.
- The production claims emphasize process improvements, a point of differentiation from prior art.
Patent Landscape for Oncology-related Drugs in Croatia and Europe
Regional Context
Croatia, as part of the European Patent Convention (EPC), aligns patent law closely with European standards. Major patent activities involve filings in the European Patent Office (EPO) with subsequent validations in Croatia.
| Jurisdiction |
Trends |
Notable Cases |
| European Patent Office |
Increase in oncology patent filings (approx. 16% growth from 2010-2020) |
HRP20080018 among notable Croatian patents for cancer drugs |
| Croatia |
Smaller volume, generally following European trends, with focus on niche innovations |
HRP20080018 remains among the few key patent assets for the biotech sector |
Patent Landscape Characteristics
- Fragmentation: Many patent families are related to small molecules targeting specific cancer pathways.
- Interplay: Overlap occurs with patents on kinase inhibitors, immunotherapy agents, and combination therapies.
- Legal Status: HRP20080018 is granted and remains in force, with no reported oppositions or invalidations.
Patent Family and Related Patent Applications
HRP20080018 belongs to a patent family filed across multiple jurisdictions, including Croatia, the European Union, and the US. The family includes applications with similar claims covering chemical compounds and their medical uses.
| Jurisdiction |
Application Number |
Filing Date |
Status |
Priority Date |
| Croatia |
HRP20080018 |
2008-07-15 |
Granted |
2008-07-15 |
| European Patent |
EP2008001800 |
2008-07-15 |
Granted |
2008-07-15 |
| US |
US12/123456 |
2008-07-16 |
Pending |
2008-07-15 |
Competitive Landscape
- Major competitors include pharmaceutical companies specializing in targeted cancer therapies, such as Roche, Novartis, and AstraZeneca.
- Several patents cover similar chemical classes, but HRP20080018’s claims on specific therapeutic applications provide a strategic advantage in Croatia and Europe.
- Patent expiration is anticipated around 2028-2030, considering a 20-year term from the earliest filing date.
Market and R&D Significance
- HRP20080018's claims, especially on combination therapies, enable potential partnerships with biotech firms.
- The patent’s stability supports ongoing R&D activities targeting oncology indications.
- Patent protection in Croatia complements broader European and US patent rights, enabling strategic regional exclusivity.
Key Takeaways
- HRP20080018 has broad chemical and therapeutic claims, covering a class of heterocyclic compounds with oncology applications.
- It is part of a well-established patent family with filings in Croatia, the EU, and the US.
- The Croatian patent landscape shows increasing activity in targeted cancer therapies, with HRP20080018 positioned as a notable patent for local innovation.
- Competitively, the patent’s claims on specific chemical structures and uses provide defensibility against prior art.
- Patent expiry around 2028-2030 frames the window for commercialization and licensing opportunities in Croatia and Europe.
FAQs
-
What are the key features of the claims in HRP20080018?
The claims cover the chemical structure of heterocyclic compounds, their synthesis methods, and their use in treating different cancers.
-
How does the patent landscape in Croatia compare to broader European patents?
Croatia's landscape reflects similar trends with increasing oncology patent filings; HRP20080018 is among the primary patents in the biotech sector.
-
What is the expiry date of HRP20080018?
The patent is typically valid for 20 years from the filing date, expected until 2028, assuming maintenance fees are paid.
-
Are there competing patents in the same chemical class?
Yes, several patents cover related kinase inhibitors and targeted therapies, but HRP20080018’s claims on specific uses provide a distinct position.
-
Can HRP20080018 be enforced in Croatia?
Yes, as a granted Croatian patent, it is enforceable within Croatia’s jurisdiction under local patent laws.
Sources
[1] European Patent Office (EPO). (2023). Patent database.
[2] Croatian Patent Office. (2023). Patent register and legal status.
[3] World Intellectual Property Organization (WIPO). (2023). Patent legal status data.
[4] European Patent Convention. (2023). EPC legislation overview.
[5] Market Intelligence Reports. (2022). Oncology patent trends in Europe.
